Skip to main content
Top
Published in: BMC Nephrology 1/2022

Open Access 01-12-2022 | Systemic Lupus Erythematosus | Case report

Systemic sclerosis complicated with renal thrombotic microangiopathy: a case report and literature review

Authors: Weiwei Kong, Yaomin Wang, Huiping Wang, Qin Zhou, Jianghua Chen, Fei Han

Published in: BMC Nephrology | Issue 1/2022

Login to get access

Abstract

Background

Systemic sclerosis (SSc) may overlap with other connective tissue diseases, which is named overlap syndrome. Scleroderma renal crisis (SRC) is a rare but severe complication of SSc. SSc related thrombotic microangiopathy (SSc-TMA) is an infrequent pathology type of SRC, while SSc-TMA accompanied by overlap syndrome is very rare.

Case presentation

This study reported a case of acute kidney injury (AKI) accompanied with overlap syndrome of SSc, systemic lupus erythematosus (SLE) and polymyositis (PM). The renal pathology supported the diagnosis of SSc-TMA but not SLE or PM-related renal injury, characterized by renal arteriolar thrombosis, endothelial cells edema, little cast in tubules and mild immune complex deposition. The primary TMA related factors (ADAMTS13 and complement H factor) were normal. Thus, this case was diagnosed as secondary TMA associated with SSc. The patient was treated with renin angiotensin system inhibitors, sildenafil, supportive plasma exchange/dialysis, and rituximab combined with glucocorticoids. After 2 months of peritoneal dialysis treatment, her renal function recovered and dialysis was stopped.

Conclusion

This study presented a case of SSc-TMA with overlap syndrome. Rituximab can be used as a treatment option in patients with high SRC risk or already manifesting SRC.
Literature
1.
go back to reference Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12(3):363–73.CrossRef Iaccarino L, Gatto M, Bettio S, Caso F, Rampudda M, Zen M, et al. Overlap connective tissue disease syndromes. Autoimmun Rev. 2013;12(3):363–73.CrossRef
2.
go back to reference Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatology. 2010;2010:543704.CrossRef Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatology. 2010;2010:543704.CrossRef
3.
go back to reference Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford, England). 2009;48(Suppl 3):iii32–5. Denton CP, Lapadula G, Mouthon L, Müller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology (Oxford, England). 2009;48(Suppl 3):iii32–5.
4.
go back to reference Dolnikov K, Milo G, Assady S, Dragu R, Braun-Moscovici Y, Balbir-Gurman A. Scleroderma renal crisis as an early presentation of systemic sclerosis. Israel Medical Association J. 2020;11(22):722–3. Dolnikov K, Milo G, Assady S, Dragu R, Braun-Moscovici Y, Balbir-Gurman A. Scleroderma renal crisis as an early presentation of systemic sclerosis. Israel Medical Association J. 2020;11(22):722–3.
5.
go back to reference van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.CrossRef van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55.CrossRef
6.
go back to reference Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019;49(3s):S14–s17.CrossRef Aringer M. EULAR/ACR classification criteria for SLE. Semin Arthritis Rheum. 2019;49(3s):S14–s17.CrossRef
7.
go back to reference Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–64.CrossRef Lundberg IE, Tjärnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–64.CrossRef
8.
go back to reference Iliopoulos G, Daoussis D. Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. Rheumatol Int. 2021. Iliopoulos G, Daoussis D. Renal dysfunction in systemic sclerosis beyond scleroderma renal crisis. Rheumatol Int. 2021.
9.
go back to reference Tang Y, Zhang W, Zhu M, Zheng L, Xie L, Yao Z, et al. Lupus nephritis pathology prediction with clinical indices. Sci Rep. 2018;8(1):10231.CrossRef Tang Y, Zhang W, Zhu M, Zheng L, Xie L, Yao Z, et al. Lupus nephritis pathology prediction with clinical indices. Sci Rep. 2018;8(1):10231.CrossRef
10.
go back to reference Cucchiari D, Angelini C. Renal involvement in idiopathic inflammatory myopathies. Clin Rev Allergy Immunol. 2017;52(1):99–107.CrossRef Cucchiari D, Angelini C. Renal involvement in idiopathic inflammatory myopathies. Clin Rev Allergy Immunol. 2017;52(1):99–107.CrossRef
11.
go back to reference Kappler S, Ronan-Bentle S, Graham A. Thrombotic Microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am. 2017;31(6):1081–103.CrossRef Kappler S, Ronan-Bentle S, Graham A. Thrombotic Microangiopathies (TTP, HUS, HELLP). Hematol Oncol Clin North Am. 2017;31(6):1081–103.CrossRef
12.
go back to reference Gallan AJ, Chang A. A new paradigm for renal thrombotic Microangiopathy. Semin Diagn Pathol. 2020;37(3):121–6.CrossRef Gallan AJ, Chang A. A new paradigm for renal thrombotic Microangiopathy. Semin Diagn Pathol. 2020;37(3):121–6.CrossRef
13.
go back to reference Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019;12(6):383–95.CrossRef Joly BS, Coppo P, Veyradier A. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Rev Hematol. 2019;12(6):383–95.CrossRef
14.
go back to reference Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the kidney. Clin J Am Society Nephrology. 2018;13(2):300–17.CrossRef Brocklebank V, Wood KM, Kavanagh D. Thrombotic Microangiopathy and the kidney. Clin J Am Society Nephrology. 2018;13(2):300–17.CrossRef
15.
go back to reference Lin C, Memon R, Sui J, Zheng XL. Identification of biomarkers in patients with thrombotic thrombocytopenic Purpura presenting with large and small ischemic stroke. Cerebrovasc Dis Extra. 2021;11(1):29–36.CrossRef Lin C, Memon R, Sui J, Zheng XL. Identification of biomarkers in patients with thrombotic thrombocytopenic Purpura presenting with large and small ischemic stroke. Cerebrovasc Dis Extra. 2021;11(1):29–36.CrossRef
16.
go back to reference Mittal A, Dijoo M, Aggarwal S, Gulati S. Rituximab to abbreviate plasma exchange in anti-CFH (complement factor H) antibody mediated atypical HUS. Iran J Kidney Dis. 2019;13(2):134–8.PubMed Mittal A, Dijoo M, Aggarwal S, Gulati S. Rituximab to abbreviate plasma exchange in anti-CFH (complement factor H) antibody mediated atypical HUS. Iran J Kidney Dis. 2019;13(2):134–8.PubMed
17.
go back to reference Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrology. 2017;12(5):825–35.CrossRef Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrology. 2017;12(5):825–35.CrossRef
18.
go back to reference Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12(11):678–91.CrossRef Woodworth TG, Suliman YA, Li W, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol. 2016;12(11):678–91.CrossRef
19.
go back to reference Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45.CrossRef Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45.CrossRef
20.
go back to reference Odler B, Hebesberger C, Hoeflechner L, Pregartner G, Gressenberger P, Jud P, et al. Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: long-term experience of a single Centre. Int J Clin Pract. 2021;75(6):e14069.CrossRef Odler B, Hebesberger C, Hoeflechner L, Pregartner G, Gressenberger P, Jud P, et al. Effect of short-interval rituximab and high-dose corticosteroids on kidney function in systemic sclerosis: long-term experience of a single Centre. Int J Clin Pract. 2021;75(6):e14069.CrossRef
21.
go back to reference Innami K, Mukai T, Kodama S, Morita Y. Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. BMJ Case Reports. 2017;2017. Innami K, Mukai T, Kodama S, Morita Y. Successful treatment using rituximab in a patient with refractory polymyositis complicated by scleroderma renal crisis. BMJ Case Reports. 2017;2017.
22.
go back to reference Chrabaszcz M, Małyszko J, Sikora M, Alda-Malicka R, Stochmal A, Matuszkiewicz-Rowinska J, et al. Renal involvement in systemic sclerosis: an update. Kidney Blood Pressure Res. 2020;45(4):532–48.CrossRef Chrabaszcz M, Małyszko J, Sikora M, Alda-Malicka R, Stochmal A, Matuszkiewicz-Rowinska J, et al. Renal involvement in systemic sclerosis: an update. Kidney Blood Pressure Res. 2020;45(4):532–48.CrossRef
23.
go back to reference Yang Z, Dong J, Yang L. Use of peritoneal Dialysis in acute kidney injury: how far away? Semin Nephrol. 2020;40(5):506–15.CrossRef Yang Z, Dong J, Yang L. Use of peritoneal Dialysis in acute kidney injury: how far away? Semin Nephrol. 2020;40(5):506–15.CrossRef
24.
go back to reference Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001;24(11):1562–6.CrossRef Greenberg SA, Amato AA. Inflammatory myopathy associated with mixed connective tissue disease and scleroderma renal crisis. Muscle Nerve. 2001;24(11):1562–6.CrossRef
25.
go back to reference Quereda C, Pascual J, Pardo A, Mampaso F, Gonzalo A, Ortuño J. Thrombotic microangiopathic nephropathy in scleroderma and lupus anticoagulant. Nephron. 1991;59(4):651–3.CrossRef Quereda C, Pascual J, Pardo A, Mampaso F, Gonzalo A, Ortuño J. Thrombotic microangiopathic nephropathy in scleroderma and lupus anticoagulant. Nephron. 1991;59(4):651–3.CrossRef
26.
go back to reference Xie X, Wang G, Cheng H, Sun L, Dong H. Scleroderma-associated thrombotic microangiopathy in overlap syndrome of systemic sclerosis and systemic lupus erythematosus: a case report and literature review. Medicine. 2020;99(41):e22582.CrossRef Xie X, Wang G, Cheng H, Sun L, Dong H. Scleroderma-associated thrombotic microangiopathy in overlap syndrome of systemic sclerosis and systemic lupus erythematosus: a case report and literature review. Medicine. 2020;99(41):e22582.CrossRef
27.
go back to reference Nanke Y, Akama H, Yamanaka H, Hara M, Kamatani N. Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy. Am J Med Sci. 2000;320(5):348–51.CrossRef Nanke Y, Akama H, Yamanaka H, Hara M, Kamatani N. Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy. Am J Med Sci. 2000;320(5):348–51.CrossRef
28.
go back to reference Cheta J, Rijhwani S, Rust H. Scleroderma renal crisis in mixed connective tissue disease with full renal recovery within 3 months: a case report with expanding treatment modalities to treat each clinical sign as an independent entity. J Investigative Medicine High Impact Case Reports. 2017;5(4):2324709617734012. Cheta J, Rijhwani S, Rust H. Scleroderma renal crisis in mixed connective tissue disease with full renal recovery within 3 months: a case report with expanding treatment modalities to treat each clinical sign as an independent entity. J Investigative Medicine High Impact Case Reports. 2017;5(4):2324709617734012.
Metadata
Title
Systemic sclerosis complicated with renal thrombotic microangiopathy: a case report and literature review
Authors
Weiwei Kong
Yaomin Wang
Huiping Wang
Qin Zhou
Jianghua Chen
Fei Han
Publication date
01-12-2022

Other articles of this Issue 1/2022

BMC Nephrology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.